利奈唑胺治疗院内MRSA肺炎的临床评价

Clinical evaluation of linezolid for MRSA-related HAP

目的评价利奈唑胺治疗院内MRSA肺炎的临床疗效和安全性。方法回顾分析13例MRSA感染的住院患者接受利奈唑胺治疗临床资料。结果临床治愈13例,不良反应发生率7.7%。结论应用利奈唑胺治疗院内MRSA肺炎能取得显著的临床效果及满意的细菌清除率,可作为院内MRSA肺炎的有效用药。

Objective To evaluate therapeutic effect and drug safety of Linezolid in MRSA-related Hospital-associated Pneumonia（HAP） therapy. Methods Retrospective analysis the clinical of 13 patients,suffered form MRSA-related HAP,who treated with Linezolid. Results All patients get cured at clinical therapy criterion,and medicine adverse-reaction rate is 7.7%. Conclusion Linezolid could provide conspicuous effectiveness and satisfactory bacterium clearance rate in treatment of MRSA-related HAP,which would become the effective medicine for this disease.